-
The Promise of PROTACs for Treating RET+ Lung Cancer
Read time: 3 minutes. RET proteins are a type of receptor tyrosine kinase—an important group of signaling molecules in healthy cells. When RET proteins are turned “on” and “off” in -
Small Cell Lung Cancer: The Dial Is Starting to Move
Read time: 6 minutes. The research community is finally beginning to gain traction and make real progress in treating small cell lung cancer (SCLC). The SCLC Hot Topic Meeting -
Real-World Examples of Patient Involvement in Designing Clinical Trials
Read time: 2 minutes. Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below -
Developing Clinical Trials that Account for the Realities of Patient Life
Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video -
Research Milestones: Celebrating LUNGevity’s 2024 Research Awards
LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in -
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Read time: 5 minutes. This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. By uncovering EGFR’s role in lung